Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States

References

• Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA. 2015;314:1021. doi:10.1001/jama.2015.10029
   PubMed Web of Science ®Google Scholar
• Cheng YJ, Kanaya AM, Araneta MRG, et al. Prevalence of diabetes by race and ethnicity in the United States, 2011–2016. JAMA. 2019;322:2389. doi:10.1001/jama.2019.19365.
   PubMed Web of Science ®Google Scholar
• Benoit SR, Hora I, Albright AL, Gregg EW. New directions in incidence and prevalence of diagnosed diabetes in the USA. BMJ Open Diabetes Res Care. 2019;7:e000657. doi:10.1136/bmjdrc-2019-000657
   Web of Science ®Google Scholar
• Beckles GL, Chou C-F. Disparities in the prevalence of diagnosed diabetes — United States, 1999–2002 and 2011–2014. MMWR Morb Mortal Wkly Rep. 2016;65:1265–1269. doi:10.15585/mmwr.mm6545a4
   PubMed Web of Science ®Google Scholar
• National diabetes statistics report | data & statistics | diabetes | CDC; 2019. Available from: https://www.cdc.gov/diabetes/data/statistics-report/index.html. Accessed September 29, 2019.
   Google Scholar
• Iglay K, Hannachi H, Howie PJ, et al. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016;32:1243–1252. doi:10.1185/03007995.2016.1168291
   PubMed Web of Science ®Google Scholar
• Raghavan S, Vassy JL, Ho Y, et al. Diabetes mellitus–related all‐cause and cardiovascular mortality in a national cohort of adults. J Am Heart Assoc. 2019;8. doi:10.1161/JAHA.118.011295
   Google Scholar
• Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17:83. doi:10.1186/s12933-018-0728-6
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61:2461–2498. doi:10.1007/s00125-018-4729-5
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322. doi:10.1056/NEJMoa1603827
   PubMed Web of Science ®Google Scholar
• Nordon C, Karcher H, Groenwold RHH, et al. The “efficacy-effectiveness gap”: historical background and current conceptualization. Value Health. 2016;19:75–81. doi:10.1016/j.jval.2015.09.2938
   Web of Science ®Google Scholar
• Carls GS, Tuttle E, Tan R-D, et al. Understanding the gap between efficacy in randomized controlled trials and effectiveness in real-world use of GLP-1 RA and DPP-4 therapies in patients with type 2 diabetes. Diabetes Care. 2017;40:1469–1478. doi:10.2337/dc16-2725
   PubMed Web of Science ®Google Scholar
• Guerci B, Charbonnel B, Gourdy P, et al. Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings. Diabetes Metab. 2019;45:528–535. doi:10.1016/j.diabet.2019.01.006
   Web of Science ®Google Scholar
• Pratley RE. The efficacy and effectiveness of drugs for diabetes: how do clinical trials and the real world compare? Diabetologia. 2014;57:1273–1275. doi:10.1007/s00125-014-3263-3
   PubMedGoogle Scholar
• Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166:1836–1841. doi:10.1001/archinte.166.17.1836
   PubMed Web of Science ®Google Scholar
• Kennedy-Martin T, Boye KS, Peng X. Cost of medication adherence and persistence in type 2 diabetes mellitus: a literature review. Patient Prefer Adherence. 2017;11:1103–1117. doi:10.2147/PPA.S136639
   PubMed Web of Science ®Google Scholar
• Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011;34:S279–84. doi:10.2337/dc11-s231
   PubMed Web of Science ®Google Scholar
• McGovern A, Tippu Z, Hinton W, Munro N, Whyte M, de Lusignan S. Comparison of medication adherence and persistence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2018;20:1040–1043. doi:10.1111/dom.13160
   PubMed Web of Science ®Google Scholar
• Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:1–19. doi:10.7573/dic.212283
   Google Scholar
• Clinformatics® Data Mart User Manual. 7.1. Optum; 2017.
   Google Scholar
• Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15:565–574. doi:10.1002/pds.1230
   PubMed Web of Science ®Google Scholar
• Kalyani RR, Saudek CD, Brancati FL, Selvin E. Association of diabetes, comorbidities, and A1C with functional disability in older adults: results from the National Health and Nutrition Examination Survey (NHANES), 1999–2006. Diabetes Care. 2010;33:1055–1060. doi:10.2337/dc09-1597
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2019;73:e285–350. doi:10.1016/j.jacc.2018.11.003
   PubMed Web of Science ®Google Scholar
• Iglay K, Cartier SE, Rosen VM, et al. Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes. Curr Med Res Opin. 2015;31:1283–1296. doi:10.1185/03007995.2015.1053048
   PubMed Web of Science ®Google Scholar
• Qiao Q, Ouwens MJ, Grandy S, Johnsson K, Kostev K. Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany. Diabetes Metab Syndr Obes Targets Ther. 2016;9:201–205. doi:10.2147/DMSO.S99732
   PubMed Web of Science ®Google Scholar
• Malmenäs M, Bouchard JR, Langer J. Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg. Clin Ther. 2013;35:795–807. doi:10.1016/j.clinthera.2013.03.021
   PubMed Web of Science ®Google Scholar
• Divino V, Boye KS, Lebrec J, DeKoven M, Norrbacka K. GLP-1 RA treatment and dosing patterns among type 2 diabetes patients in six countries: a retrospective analysis of pharmacy claims data. Diabetes Ther. 2019;10:1067–1088. doi:10.1007/s13300-019-0615-5
   PubMed Web of Science ®Google Scholar
• Wilke T, Mueller S, Groth A, et al. Non-persistence and non-adherence of patients with type 2 diabetes mellitus in therapy with GLP-1 receptor agonists: a retrospective analysis. Diabetes Ther. 2016;7:105–124. doi:10.1007/s13300-015-0149-4
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844. doi:10.1056/NEJMoa1607141
   PubMed Web of Science ®Google Scholar
• Federici MO, McQuillan J, Biricolti G, et al. Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Italy: a retrospective cohort study. Diabetes Ther. 2018;9:789–801. doi:10.1007/s13300-018-0396-2
   PubMed Web of Science ®Google Scholar
• Evans M, McEwan P, O’Shea R, George L. A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice. Diabetes Ther. 2013;4:27–40. doi:10.1007/s13300-012-0015-6
   PubMed Web of Science ®Google Scholar
• Nyeland ME, Ploug UJ, Richards A, et al. Evaluation of the effectiveness of liraglutide and sitagliptin in type 2 diabetes: a retrospective study in UK primary care. Int J Clin Pract. 2015;69:281–291. doi:10.1111/ijcp.12575
   PubMed Web of Science ®Google Scholar
• Dhesi B, Chauhan H, Basu A. Audit of clinical practice in the use of incretin mimetic agents for the management of patients with type 2 diabetes. Pract Diabetes. 2013;30:159–162. doi:10.1002/pdi.1767
   Google Scholar
• Coleman CI, Pandya S, Wang L, et al. Treatment patterns, glycemic control and bodyweight with canagliflozin 300 mg versus GLP1RAs in Type II diabetes patients. J Comp Eff Res. 2019;8:889–905. doi:10.2217/cer-2019-0002
   Web of Science ®Google Scholar
• Thomsen RW, Baggesen LM, Søgaard M, et al. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4734 people with type 2 diabetes. Diabetologia. 2015;58:2247–2253. doi:10.1007/s00125-015-3698-1
   PubMed Web of Science ®Google Scholar
• Iepsen EW, Lundgren J, Dirksen C, et al. Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss. Int J Obes. 2015;39:834–841. doi:10.1038/ijo.2014.177
   PubMed Web of Science ®Google Scholar